BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Clobazam: Additional Phase III data

Additional data from the mITT population (n=217) of a double-blind, international Phase III trial showed that mid- and high-dose clobazam significantly reduced the average weekly rate of drop seizures from the 4-week baseline period to the 12-week maintenance period, the primary endpoint, by 49.4% and 68.3%, respectively, vs. 12.1% for placebo (p=0.0015 and p<0.0001, respectively). Low-dose clobazam reduced the measure by 41.2%, but did not meet the pre-defined criteria of p<=0.01 for achieving statistical significance on the primary endpoint (p=0.012)....

Read the full 379 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >